Prescription drug · ANDA
Fenofibric Acid NDC 69315-282
Fenofibric acid 135 mg/1 · Capsule, Delayed release · Oral · Leading Pharma, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 69315-282-09 | 6931502820969315028209 | 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (69315-282-09)Marketed from Jul 18, 2019 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Fenofibric Acid
- Generic name (nonproprietary)
- fenofibric acid
- Active ingredients
- Fenofibric acid — 135 mg/1
- Dosage form
- Capsule, Delayed release
- Route
- Oral
- Labeler
- Leading Pharma, LLCNDC labeler code 69315
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 211626
- Marketing start
- Listing expires
- Identifiers
- Product ID 69315-282_17afd47a-c2eb-411b-8b6c-6c1ce709dbbfSPL ID 17afd47a-c2eb-411b-8b6c-6c1ce709dbbfSPL set ID daa488be-f580-430c-a72c-80ac31bb3e40RxCUI 828373, 828379UNII BGF9MN2HU1
- Pharmacologic class
- Peroxisome Proliferator Receptor alpha Agonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N469315028209followed by a unit qualifier and the quantityPackage 69315-0282-09. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Fenofibric acid delayed-release capsules are indicated as adjunctive therapy to diet: to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL). to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. Limitations of Use Markedly elevated levels of serum TG (e.g., > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been determined [see Warnings and Precautions (5.7) ] . Fenofibrate did not reduce coronary heart disease morbidity and mortality in two l…
Excerpt only. Read the full label for complete information.
About NDC 69315-282
- What is NDC 69315-282?
- 69315-282 is the product NDC for Fenofibric Acid, Fenofibric acid 135 mg/1 capsule, delayed release, listed with the FDA by Leading Pharma, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Fenofibric Acid.
- What is the active ingredient?
- Fenofibric acid.
- Who is the labeler?
- Leading Pharma, LLC, NDC labeler code 69315. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Fenofibric Acid?
- 13 other product NDCs are listed under this name. See all Fenofibric Acid NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Fenofibric Acid products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Fenofibric Acid | Fenofibric acid 45 mg/1 | Capsule, Delayed releaseOral | Amneal Pharmaceuticals of New York LLC | 0115-1324 | 00115-1324-10 |
| Fenofibric Acid | Fenofibric acid 135 mg/1 | Capsule, Delayed releaseOral | Amneal Pharmaceuticals of New York LLC | 0115-1325 | 00115-1325-10 |
| Fenofibric acid | Choline fenofibrate 45 mg/1 | Capsule, Delayed releaseOral | Macleods Pharmaceuticals Limited | 33342-294 | 33342-0294-1033342-0294-12 |
| Fenofibric acid | Choline fenofibrate 135 mg/1 | Capsule, Delayed releaseOral | Macleods Pharmaceuticals Limited | 33342-295 | 33342-0295-1033342-0295-56 |
| Fenofibric Acid | Fenofibric acid 45 mg/1 | Capsule, Delayed releaseOral | Aurobindo Pharma Limited | 59651-216 | 59651-0216-90 |
| Fenofibric Acid | Fenofibric acid 135 mg/1 | Capsule, Delayed releaseOral | Aurobindo Pharma Limited | 59651-217 | 59651-0217-90 |
| Fenofibric Acid | Fenofibric acid 45 mg/1 | Capsule, Delayed releaseOral | Leading Pharma, LLC | 69315-281 | 69315-0281-09 |
| Fenofibric Acid | Fenofibric acid 135 mg/1 | Capsule, Delayed releaseOral | Alembic Pharmaceuticals Limited | 46708-245 | 46708-0245-3046708-0245-9046708-0245-91 |
| Fenofibric Acid | Fenofibric acid 45 mg/1 | Capsule, Delayed releaseOral | Alembic Pharmaceuticals Limited | 46708-244 | 46708-0244-3046708-0244-9046708-0244-91 |
| Fenofibric Acid | Fenofibric acid 45 mg/1 | Capsule, Delayed releaseOral | Alembic Pharmaceuticals Inc. | 62332-244 | 62332-0244-3062332-0244-9062332-0244-91 |
Other NDCs under ANDA 211626
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Fenofibric Acid | Fenofibric acid 45 mg/1 | Capsule, Delayed releaseOral | Leading Pharma, LLC | 69315-281 |